Recommandations françaises du Comité de transplantation de l’Association française d’urologie (CTAFU) : cancer de la prostate localisé chez le patient transplanté rénal ou en attente de transplantation

Culty, T.; Goujon, A.; Defortescu, G.; Bessede, T.; Kleinclauss, F.; Boissier, R.; Drouin, S.; Branchereau, J.; Doerfler, A.; Prudhomme, Thomas; Matillon, X.; Verhoest, G.; Tillou, X.; Ploussard, Guillaume; Rozet, François; Méjean, A.; Timsit, Marc Olivier

doi:10.1016/j.purol.2020.04.027

Cited by 4 publications

(8 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We observed no recurrence or PCa-related death after RT, suggesting that our current protocols and recommended delays lead to satisfying cancer control. 6 One of the first series of transplant recipients with a history of PCa Our study nevertheless had a few limits. Having multiple centers participating in the study provided a large collection of data, but with practices varying from center to center.…”

Section: Discussionmentioning

confidence: 93%

“…Data were extracted from March 1, 2021 to June 1, 2021. In accordance with the Renal Transplantation Committee of the French Urological Association (CTAFU) recommendations, PCa screening was performed at time of listing using DRE and PSA dosage in patients above 50 years old candidates for RT 6 . The delay for active listing after PCa treatment was decided according to French Association of Urology (AFU) guidelines (Table 1).…”

Section: Methodsmentioning

confidence: 99%

“…It was a retrospective observational study including all patients with newly diagnosed PCa at the time of transplant listing for RT from Jan- didates for RT. 6 The delay for active listing after PCa treatment was decided according to French Association of Urology (AFU) guidelines (Table 1). 6 All patients with history of PCa prior to transplant listing were excluded from the study.…”

Section: Participants and Settingsmentioning

confidence: 99%

“…6 The delay for active listing after PCa treatment was decided according to French Association of Urology (AFU) guidelines (Table 1). 6 All patients with history of PCa prior to transplant listing were excluded from the study.…”

Section: Participants and Settingsmentioning

confidence: 99%

“…French Association of Urology guidelines for minimum waiting period after prostate cancer treatment according to d'Amico risk group in patients on waiting list for renal transplantation 6. …”

mentioning

confidence: 99%

See 4 more Smart Citations

Impact of newly diagnosed prostate cancer at time of evaluation for renal transplantation

Poinard

Bessède

Barrou

et al. 2023

Clinical Transplantation

View full text Add to dashboard Cite

Systematic screening for prostate cancer is widely recommended in candidates for renal transplant at the time of listing. There are concerns that overdiagnosis of low-risk prostate cancer may result in reducing access to transplant without demonstrated oncological benefits. The objective of the study was to assess the outcome of newly diagnosed prostate cancer in candidates for transplant at the time of listing, and its impact on transplant access and transplant outcomes according to treatment options. This retrospective study was conducted over 10 years in 12 French transplant centers. Patients included were candidates for renal transplant at the time of prostate cancer diagnosis. Demographical and clinical data regarding renal disease, prostate cancer, and transplant surgery were collected. The primary outcome of the study was the interval between prostate cancer diagnosis and active listing according to treatment options. Overall median time from prostate cancer diagnosis to active listing was 25.0 months [16.4-40.2], with statistically significant differences in median time between the radiotherapy and the active surveillanceThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Methodsmentioning

confidence: 99%